MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO) today announced positive Phase III clinical results from its pivotal efficacy study of NATRECOR(R) BNP for the treatment of acute congestive heart failure (CHF). In the study, NATRECOR produced improvements in patients' ...